WITHUS PHARMACEUTICALLTD Balance Sheet Health
Financial Health criteria checks 4/6
WITHUS PHARMACEUTICALLTD has a total shareholder equity of ₩90.3B and total debt of ₩19.4B, which brings its debt-to-equity ratio to 21.5%. Its total assets and total liabilities are ₩130.8B and ₩40.5B respectively. WITHUS PHARMACEUTICALLTD's EBIT is ₩7.9B making its interest coverage ratio -60.3. It has cash and short-term investments of ₩11.2B.
Key information
21.5%
Debt to equity ratio
₩19.42b
Debt
| Interest coverage ratio | -60.3x |
| Cash | ₩11.19b |
| Equity | ₩90.28b |
| Total liabilities | ₩40.50b |
| Total assets | ₩130.78b |
Recent financial health updates
No updates
Recent updates
Here's What Withuspharmaceutical Co.,Ltd.'s (KOSDAQ:330350) Shareholder Ownership Structure Looks Like
Feb 17
Calculating The Intrinsic Value Of Withuspharmaceutical Co.,Ltd. (KOSDAQ:330350)
Jan 13
We're Not Counting On WithuspharmaceuticalLtd (KOSDAQ:330350) To Sustain Its Statutory Profitability
Dec 09Financial Position Analysis
Short Term Liabilities: A330350's short term assets (₩58.2B) exceed its short term liabilities (₩31.0B).
Long Term Liabilities: A330350's short term assets (₩58.2B) exceed its long term liabilities (₩9.5B).
Debt to Equity History and Analysis
Debt Level: A330350's net debt to equity ratio (9.1%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if A330350's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: A330350's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: A330350 earns more interest than it pays, so coverage of interest payments is not a concern.